These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 18367829

  • 1. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
    Ram R, Gafter-Gvili A, Okon E, Pazgal I, Shpilberg O, Raanani P.
    Acta Haematol; 2008; 119(2):104-7. PubMed ID: 18367829
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML).
    Thakral B, Higa B, Venkataraman G, Velankar MM.
    Pathology; 2012 Jan; 44(1):59. PubMed ID: 22157697
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S.
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
    Michael M, Antoniades M, Lemesiou E, Papaminas N, Melanthiou F.
    Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
    [Abstract] [Full Text] [Related]

  • 15. [Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy].
    Sumi M, Tauchi T, Shimamoto T, Sshida G, Nakajima A, Ito Y, Ohyashiki K.
    Rinsho Ketsueki; 2002 Sep; 43(9):868-70. PubMed ID: 12412295
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
    Zaucha JM, Wyrowinska E, Prejzner W, Calbecka M, Hellmann A.
    Clin Lab Haematol; 2006 Jun; 28(3):208-10. PubMed ID: 16706939
    [Abstract] [Full Text] [Related]

  • 18. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
    Scheinfeld N.
    J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.